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Abstract
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For this special issue on 90 years of polarography, the following personal account describes how
my early research in electrochemistry and polarography in the laboratory of Prof. Petr Zuman led
to a major research effort in the determination of proteins for cancer detection and monitoring. It
reviews the very recent history of nanoparticle labels and multiplexed detection in protein
immunosensors. It then describes our journey of discovery that has led to ultrasensitive protein
immunosensors achieved by combining nanostructured electrodes with particles labeled with up to
½ million enzymes that can detect down to as little as 1 fg mL−1 protein in diluted serum. Our
most mature multiple protein detection system is a microfluidic device with eight sensors coated
with 5-nm gold nanoparticles that uses off-line protein detection with heavily labeled magnetic
particles. This approach has led to reliable sub pg mL−1 detection limits for multiple proteins,
provides excellent correlation with referee ELISA methods, and is currently being used for
validation of panels of biomarkers for oral and prostate cancer. The article ends with a section on
future perspectives.
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1. Introduction
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It is a great honor for me to contribute this Personal Account article in the special issue on
electrochemistry honoring the 90th anniversary of the discovery of polarography by Jaroslav
Heyrovsky in 1922. Polarography was the very first quantitative electroanalytical technique,
since prior to this time the irreproducibility of electrode surfaces led to serious problems in
reproducibility. Heyrovsky’s genius was to use a dropping mercury electrode (DME),
featuring renewal of a new, clean Hg surface every few seconds when the drop fell off and a
new one began to form. Heyrovsky became Professor of Physical Chemistry at Charles
University in Prague and went on to found and head the Polarographic Institute in Prague,
which for many years was the international leader in polarographic research as well as in the
development of new electrochemical instrumentation. The popularity of the DME has waned
in recent years, due to the toxicity of mercury and our greatly improved understanding of
how to reproducibly prepare solid electrode surfaces. However, the discovery of
polarography facilitated extensive experience in quantitative experiments that extrapolated
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to solid electrodes, and that led directly to the wide variety of subsequent electroanalytical
applications that we find now at the beginning of the 21st century.
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This article deals with the development of electrochemical immunosensors that detect
proteins as well as viruses and bacteria. These biosensors are part of a long list of
electroanalytical methods designed to help solve biological problems. Examples include
enzyme-based home-use electrochemical biosensors for measuring blood glucose by
diabetic patients,1 biosensors that detect DNA for genetic analysis and protein biomarkers
for diseases,2,3 and electrochemiluminescence (ECL) detectors for nucleic acids and
proteins.4,5
It is personally rewarding to me to contribute to this issue as I am the scientific grandson of
Jaroslav Heyrovsky, having earned my Ph.D. in Chemistry at Clarkson University in 1979
under the direction of Professor Petr Zuman, who was Heyrovsky’s Ph.D. student at Charles
University. Petr Zuman also served as the head of the Organic Electrochemistry Division of
Heyrovsky’s Polarographic Institute in the 1950s and 60s before moving briefly to the
University of Birmingham in the UK, and then on to Clarkson in the US in 1970.
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My graduate education with Prof. Zuman in the late 1970s involved mainly mechanistic
organic electrochemistry. The skills I developed there in fundamental electrochemistry and
instrumentation provided me with an excellent background for a later move into independent
bioelectrochemical research at University of Connecticut. For many years prior to the
present century, our work in Connecticut involved catalytic electrochemical decomposition
of organic pollutant molecules in detergent dispersions6 as well as fundamental studies of
protein film voltammetry.7 I first developed an interest in electrochemical immunosensors in
2001 during a sabbatical period in the laboratory of Prof. Malcolm Smyth at the Irish
National Center for Sensor Research at Dublin City University. Our group has since
translated this interest into a major research effort involving biologists, materials scientists,
statisticians, and clinical researchers in the US and around the world. Major colleagues in
this group include nanomaterials scientist Prof. Folios Papadimitrakopoulos at the
University of Connecticut, and cancer biologists at the US National institutes of Health led
by Dr. Silvio Gutkind and Dr. Vyomesh Patel. In the sections below, I begin with a brief
history of electrochemical immunosensors, then provide an overview of the advantages of
nanoparticles in these immunosensors. I then focus the remainder of the review on recent
contributions of our laboratory to ultrasensitive detection of cancer biomarker proteins with
nanoparticle-enhanced electrochemical immunosensors and immunoarrays.

NIH-PA Author Manuscript

Our research in this area focuses on developing electrochemical arrays for ultrasensitive
detection of multiple biomarker measurements for cancer diagnostics. The US National
Institutes of Health defines biomarkers as “molecules that can be objectively measured and
evaluated as indicators of normal or disease processes and pharmacologic responses to
therapeutic intervention”.8 Our research focuses on panels of biomarker proteins that can
provide a “snapshot” of patient status with regard to the disease.13,14 Cancer detection and
monitoring demands the ability to detect amounts of protein below the normal patient levels
for the least abundant protein. It requires good sensitivity for all protein biomarkers at
normal and elevated levels. Detection limits well below the pg mL−1 level and good
sensitivity up to hundreds of ng mL−1 will be necessary for the broadest applicability. For
example, prostate specific antigen (PSA), a clinical biomarker for prostate cancer, has a
normal serum level of 0.5–3 ng mL−1, while elevated levels of 4–10 ng mL−1 indicate the
possibility of prostate cancer.9 Interluekin-6 (IL-6) is a biomarker protein that is
overexpressed in head and neck, prostate, lung, multiple myeloma and renal cancers.10 Its
normal serum level is <6 pg mL−1 while levels in cancer patients can elevate to hundreds of
pg mL−1 or more. Detection of both biomarkers in serum illustrates the fact that detection
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needs to be viable over a broad range of concentrations that are often different for different
proteins. This is all the more important since single biomarkers usually have insufficient
predictive ability, and devices that measure panels of 4–10 proteins will ultimately be
needed for reliable cancer diagnostics.13,14

2. Development of Electrochemical Immunoassays and Immunosensors
The basic principles of electrochemical immunoassays are illustrated by Figure 1, which
includes some aspects of nanoparticle enhancement that we will discuss later. Basically,
primary antibodies are attached to a solid substrate or an electrode to selectively capture the
analyte protein from the sample. After washing, a secondary antibody with a label attached
is added, and binds selectively to the protein on the surface. This label, shown as an enzyme
in Figure 1, is then detected electrochemically.11-13 This general approach was adapted from
enzyme-linked immunosorbent assays (ELISA), which have served as workhorse methods
for detection of proteins for many years.14,15 ELISA uses optical detection of a colored
enzyme reaction product and, while still widely used, has known limitations in multiplexing,
analysis time, and sample size.
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Bill Heinemann and co-workers pioneered electrochemical immunosensing in the 1980s,
utilizing sandwich immunoassays with enzyme label alkaline phosphatase that produces
electroactive products. In his group’s approach, the capture antibodies in the sandwich
immunoassay reside in a flow system upstream from the detector. Products formed from the
enzyme label are transported by a chromatographic or fluidic system to the detecting
electrode.16,17 Advances have included interdigitated electrodes to achieve high
sensitivity,18 and incorporation into microfluidic devices.19 This team has achieved
excellent detection limits (DLs) in the pg mL−1 to ng mL−1 range for small molecules and
proteins.
Efforts in the 1990s began to be directed toward developing single analyte enzyme-linked
electrochemical immunosensors by researchers including Malcolm Smyth, Gerry Guilbault
and others.12,20-23 Here, the antibodies (Ab) are attached directly to the sensor electrode, and
antigen capture, secondary antibody binding, and label detection are all done on the same
surface. The sandwich format provides the most selective and sensitive assays (see Figure
1).
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In addition to alkaline phosphatase, horseradish peroxidase (HRP) is a suitable label. When
activated by hydrogen peroxide, the iron heme HRP enzyme is converted to an FeIV=O form
that can be reduced on electrodes at low potentials.24 Many other types of labels have been
used, including glucose oxidase, electroactive metal ions and complexes, nanoparticles,25,26
conductive polymers, and liposomes loaded with electroactive compounds.23 Savéant et al.
analyzed electrochemical responses of enzyme labels in detail, and identified key
immunosensor sensitivity factors.27-29
A critical issue in immunoassays is minimization of non-specific binding (NSB) of
interfering species in samples such as serum or blood, as well as NSB of the labeled Ab2
that arises when this signal producing species is bound to non-antigen sites on the sensor. In
labeled assays, non-enzyme Ab2 bound to sites other than the analyte protein still gives a
signal, but it is not proportional to the analyte protein concentration. This can increase
detection limits and degrade sensitivity. NSB is usually minimized by washing with a
cocktail that includes casein or bovine serum albumin and detergents in NSB-blocking steps.
The literature suggests that tailoring the sensor surface with appropriate chemical groups can
also inhibit protein adsorption, and one of the most effective surfaces features polyethylene
glycol (PEG) moieties.23,30,31 Such functionalized surfaces, although useful, may still
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permit small amounts of NSB that could significantly increase background in the pg to ng
mL−1 analyte concentration ranges.
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Multiplexing has also been achieved with electrochemical immunosensors. For example,
iridium oxide sensor chips enabled simultaneous electrochemical immunoassays using
alkaline phosphatase-labeled Ab2 and detection of product hydroquinone with DLs of 1–3
ng mL−1 for up to eight cancer biomarker proteins.32-34 Results showed good correlation
with ELISA. Sensors coated with a composite DNA dendrimer/conducting polymer were
used in a 16-sensor immunoelectrochemical array.35 Protein biomarkers for oral cancer
(IL-8 and IL-1b) and IL-8mRNA were measured using HRP-labeled secondary antibodies in
buffer with DL of 100–200 fg mL−1 for the proteins and 10 aM for the IL-8 mRNA. In
saliva, DLs degraded to 4 fM IL-8mRNA and 7.4 pg mL−1 IL-8.36
Unlabeled electrochemical immunoassays can be achieved with impedance or capacitance
sensors, field-effect transistors (FETs) or nanowire transistors.37,38 Ultrasensitive nanowire
transistors require significant future development and cost reductions before they can
compete with more accessible, lower-cost procedures. A less-sensitive nanoribbon sensor
coupled with a microfluidic device that measures cancer biomarker proteins also shows
promise.39

NIH-PA Author Manuscript

3. Nanoparticle-Based Electrochemical Immunosensors
When I was a Ph.D. student in the 1970s, we in Petr Zuman’s group were members of the
Institute of Colloid and Surface Science at Clarkson University. In those days, consistent
fabrication of monodisperse gold or metal oxide particles with diameters under 20 nm would
have been a multi-year effort. Since that time, simple, rapid methodologies for nanoparticle
fabrication have emerged that have enabled many new applications. Ready availability of
these particles has led to new opportunities for ultrasensitive approaches to electrochemical
protein sensors.11,13,25,31,40-43 Sandwich immunosensor strategies using secondary
antibody(Ab2)-nanoparticle bioconjugates have included dissolvable nanoparticles leading
to electroactive ions, Ab2-nanoparticles with thousands of enzyme labels, and Ab2nanoparticles with multiple redox probes (Figure 2).25,30,41,44-47 These approaches greatly
enhance sensitivity by providing a large number of labels for each protein bound on the
sensor surface.
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Nanostructured sensor surfaces can provide additional increases in sensitivity by providing
high surface areas enabling attachment of a large number of capture antibodies,13,48 and by
facilitating better access of protein analytes to these antibodies.49 For example,
nanostructured immunosensors have been made in our laboratory using films of carbon
nanotubes30,31,41 or gold nanoparticles,50 and in Shana Kelley’s lab by engineering highly
nanostructured sensor surfaces by electrodepositing gold.49,51
Nanoparticle labels in immunoassays were first reported by Delequaire et al.52 The metals in
the nanoparticles served as labels after dissolution of the particles. After the antibodies
capture analyte proteins, Ab2-nanoparticles are added to bind to them, and an NSB blocking
wash is done. Then, the nanoparticles are dissolved in acid to produce high concentrations of
electroactive metal ions. With gold nanoparticle-Ab2 labels, Au3+ released by acid
dissolution was detected by anodic stripping voltammetry to give a 3 pM DL for IgG in
buffer. Joe Wang and his team further enhanced sensitivity25 by using cyclic accumulation
of gold nanoparticles (AuNPs) and using gold particles to catalyze Ag precipitation,
detecting the large amounts of metal ions released by stripping analysis. For example, Ag
deposition provided a 0.5 ng mL−1 (22 pM) DL for cardiac troponin I.53 Multiple AuNPs
were attached to larger Au spheres and used for Ag deposition.25 Similarly, magnetic
particles were decorated with CdS quantum dots (Qdots), isolated magnetically, then
Chem Rec. Author manuscript; available in PMC 2012 August 01.
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dissolved for potentiometric stripping detection of Cd.25 Ag deposition also afforded
ultrasensitive conductivity immunoassays of human IgG in buffer.54 A novel antibodycoated nanopore immunoassay was developed that filters blood and detects proteins utilizing
gold nanoparticle labels, then depositing Ag. Detection relies on the rate of decreased
diffusion of an electroactive probe through the pores. This method was used to detect IgGs
including a cancer biomarker in whole blood.55 Other strategies include loading Ab2nanoparticles or Ab2-polymer beads with electroactive labels such as ferrocene, and later
releasing the labels for detection.25,26,30,40
Multiplexed protein assays using nanoparticle approaches were also developed.25 “Bar
code” labeling of secondary antibodies with distinct nanoparticles having different
electrochemical characteristics have been used. For example, different Ab2’s can be labeled
with dissolvable nanoparticles or Qdots of different metals that give ions with different
reduction potentials. For example, cadmium, zinc, copper, and lead sulfide Qdots were
attached to four individual Ab2’s to measure the four different cognate proteins.56 The Qdots
were then dissolved to yield four different metal ions, each tracking a different protein, and
measured by electrochemical stripping analysis. Multiple-metal rods, spheres or alloy rods
have also been used as multiplexing tools in immunoassays. Upon dissolution, these
materials give a series of metal stripping peaks whose potentials and relative intensities are
associated with individual analyte proteins.25
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4. Enzyme-Nanoparticle Bioconjugates for Ultrasensitive Electrochemical
Immunoassays
Nanoparticles can be coated with high loadings of enzymes and secondary antibodies to
amplify signals in sandwich immunoassays. Joe Wang pioneered this approach for
ultrasensitive detection of DNA and proteins.57 Joe’s group used multiwall carbon
nanotubes (MWCNTs) derivatized with thousands of copies of alkaline phosphatase and
secondary antibodies, and reported femptomolar detection levels for proteins in buffer.
Alternate electrostatic layer-by-layer deposition of alkaline phosphatase with oppositely
charged polyions on MWCNTs was used to make alternative detection particles and achieve
a DL of ca. 70 aM for IgG in buffer.58
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In collaboration with Bernard Munge of Salve Regina University, a former postdoctoral
fellow with Wang, our research team began to use multi-enzyme labeled nanoparticles in
immunosensor protocols for PSA, IL-6, and other prostate cancer biomarkers.13,31,44,41,59-61
Sensitivity was promoted further by using nanostructured electrodes featuring densely
packed films of ca. 30 nm long upright single wall carbon nanotube (SWCNT) forests,62,63
or 5 nm glutathione-decorated AuNPs.50 These high-area sensor surfaces feature
populations of carboxylate groups ready for attachment of large amounts of capture
antibodies48 by amidization. AFM images of these surfaces illustrate their large areas and
changes in surface morphology that result when capture antibodies are attached (Figure 3).
We used nanostructured sensors coated with SWCNT forests or AuNP films for sandwich
immunoassays for prostate cancer biomarker PSA.31,41,50,59 As in Figure 2a, conventional
secondary antibodies (Ab2) conjugated with single or multiple HRPs, as well as carbon
nanotubes (CNT) or magnetic particles conjugated with Ab2 and large copy numbers of
HRPs (Figure 2c,g), were used for detection. When these heavily labeled detection
particles64 replace HRP-Ab2 in immunoassays (cf. Figure 1), the large number of labels per
captured protein analyte greatly enhances sensitivity.
We used rotating disk amperometry to measure immunosensor responses using H2O2 to
activate the enzyme, and hydroquinone (HQ) to mediate the reduction of the resulting

Chem Rec. Author manuscript; available in PMC 2012 August 01.

RUSLING

Page 6

NIH-PA Author Manuscript

ferryloxy form of HRP (PFeIV=O). This approach produces a steady-state amperometric
current proportional to concentration (see Figures 4 and 5). The chemistry of the detection is
illustrated in Scheme 1.
Immunosensors for PSA in serum using multi-labeled CNT-HRP-Ab2 particles using this
approach gave detection limits (DL, 3 times the average noise level above the zero PSA
control) of 4 pg mL−1 (150 fM).62 SWCNT forests provided 5 to 10-fold better sensitivity
than immunosensors without nanotubes because of a large increase in density of Ab1
compared to that on a flat immunosensor, which was recently confirmed.48 SWCNT
immunosensors were used to measure PSA levels in 1000 prostate cancer cells laser
dissected from prostate tissue (Figure 4). These immunosensors were also used to obtain a
0.5 pg mL−1 DL for IL-6 released from a variety of oral cancer cells into cell growth
media.61
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AuNP-coated sensors were made by depositing 5 nm glutathione-decorated AuNPs onto a
0.5 nm polycation layer on pyrolytic graphite (PG). Glutathione terminates in carboxyl
groups that provided functionality to attached capture antibodies to the AuNP layer.
Sensitivity was further improved by using detection particles with Ab2 and ca.7500 HRPs
attached onto 1 μm magnetic beads.50 Using these multiply labeled magnetic beads with
AuNP platforms (Figure 5), the detection limit was 0.5 pg mL−1 (20 fM) PSA in serum,
eight-fold better, and sensitivity was four-fold better than SWCNT forest immunosensors.
Controls (a) and (b) in Figure 5A show that the dense AuNP platform also provides
enhanced sensitivity over immunosensors without AuNPs.
SWCNT forest and AuNP immunosensors gave excellent correlations with ELISA results
for determination of PSA in serum from human cancer patients.50,62 A four-electrode
SWCNT forest array was used to detect PSA, IL-6, platelet factor-4, and prostate specific
membrane antigen simultaneously.65 Since these four proteins are present in different
concentration ranges in the serum, we combined multiply and single labeled antibodies to
achieve the necessary individual sensitivities. Excellent correlations with single-protein
ELISAs were obtained for samples from cancer patients and cancer-free controls (Figure 6).
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Paramagnetic beads are very useful to aid in protein capture, separation, and transport in
immunoassays. Paramagnetic labeled particles have a distinct advantage over non-magnetic
particles since only a simple magnet is required to separate and manipulate them, and
filtration and centrifugation are avoided.66 They can also be used to achieve magnetic
position control in microfluidic devices. We have now attached secondary antibodies and
7,500 to 500,000 HRP labels to magnetic particles for immunosensor applications. The
number of HRP units can be adjusted depending on the sensitivity needs for specific analyte
proteins. Individual sensors have been developed that achieved DLs well below 1 pg mL−1
for PSA, IL-6, IL-8, and matrix metalloprotein-3 (MMP3).50,67-70 Our record, in
collaboration with Bernard Munge, is an unprecedented DL of 1.0 fg mL−1 for IL-8 using
magnetic bead bioconjugates with a half-million HRP units each. An added advantage is that
tens of thousands of antibodies can be included on 1 μm beads, promoting binding of
analyte proteins to the beads at concentrations well below what can be achieved with a
single antibody.
We recently coupled the immunosensor approaches described above into a microfluidic
system featuring an eightbiosensor array. This simple microfluidic immunoassay system
(Figure 7) features AuNP sensor electrodes, and is currently being used to validate
biomarker panels. We used off-line protein capture by multiply labeled magnetic particles to
achieve very low DLs of 10–300 fg mL−1 for proteins in serum. Other advantages include
multiplexing capability, speed (ca. 1 hr per assay), and low cost.
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Figure 8 shows calibration data obtained for the simultaneous detection of PSA and IL-6 in
diluted serum using the microfluidic system in Figure 7.72 After off-line capture of the
proteins by labeled magnetic particles, these particles are separated and washed. They are
then injected into the device via the injector sample loop, and the flow is stopped when they
reach the measuring chamber. After 15 min to allow the particles to bind to the capture
antibodies on the electrodes and suppression of NSB by the appropriate blocking cocktail,
flow is resumed and a mixture of H2O2 and hydroquinone is injected to develop the signal.
The device gives low noise peaks in the pg mL−1 range with negligible crosstalk72 (Figure
8). Excellent dynamic ranges and DLs of ca. 0.2 pg mL−1 were obtained for both proteins in
assays that require only 2–5 μL of diluted serum. Even if not required to determine panel
proteins, such very high sensitivity will allow sample dilution to further minimize nonspecific binding of interferences.
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We are developing several alternatives to the above approach for ultrasensitive multi-protein
measurements. We recently reported a prototype multi-protein array using
electrochemiluminescence (ECL) detection, which involves electrochemically generated
light emission from a luminescent label. The label used is tris (2,2′-bipyridyl) ruthenium(II),
[RuBPY], which initiates ECL when it reacts in a complex pathway with oxidized forms of
sacrificial reductant tripropylamine.4,73 An advantage of ECL is that an electrode turns on
the light, avoiding light sources and sophisticated optics required for conventional
luminescence approaches.
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We fabricated an immunosensor array on a conductive pyrolytic graphite chip (1 × 1 in.)
that features upright single-wall carbon nanotube forests (SWCNTs) attached at the bottoms
of 10 μL wells with polymer walls (Figure 9).74 Antibodies to capture the analyte proteins
were attached to the carboxylate groups on the ends of the SWCNTs. This array requires
only a single connection to a potentiostat to achieve ECL, avoiding the individually
addressable sensor electrodes required above. Silica nanoparticles containing [Ru(bpy)3]2+
and secondary antibodies (RuBPY-silica-Ab2) were synthesized for highly sensitive twoanalyte detection. Antibodies to PSA and IL-6 were attached to the same RuBPY-silica-Ab2
particle. A sandwich immunoassay protocol was used in which antibodies on the SWCNTs
in the wells capture analyte proteins from 10 μL of sample. The 100 nm RuBPY-silica-Ab2
particles are added to bind to the captured proteins. Then, detection is initiated in the
microwells by electrochemical oxidation of tripropylamine (TprA), which generates
emission of ECL from [Ru(bpy)3]2+ in the 100 nm particles. ECL is measured in an open
top electrochemical cell placed in a dark box with a charge-coupled device (CCD) camera
above it (Figure 10). The hydrophobic polymer wall barriers confine reagents and sample in
the wells, and enable simultaneous assays of different proteins in serum while avoiding
cross-contamination. DLs in serum were 1 pg mL−1 for PSA and 0.25 pg mL−1 for IL-6.74
Measurements of PSA and IL-6 in the serum of prostate cancer patients agreed well with
single-protein ELISA assays. These microwell ECL immunoarrays provide a simpler though
slightly less sensitive approach to detecting multiple proteins than the microfluidic
electrochemical assays described above. Both systems are under further development, and
each is expected to have advantages in different diagnostic scenarios.

5. Summary and Future Perspectives
This article describes our recent progress in the development of ultrasensitive multiplexed
electrochemical devices to detect biomarker proteins aimed for use in clinical cancer
diagnostics. There is a great need for such devices since current clinical practice often
involves single biomarkers with low predictive power, qualitative physical examinations,
and biopsies coupled with pathological identification of the cancer. Certainly, measurement
of a reliable panel of multiple biomarker proteins from a blood sample would be an

Chem Rec. Author manuscript; available in PMC 2012 August 01.

RUSLING

Page 8

enormous advance for cancer detection, for therapy monitoring, and for patient comfort and
stress reduction.
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Once devices are available that fit our requirements, what panels do we measure? The
choice of these panels is not trivial. Reliability of the panels chosen needs to be validated
quantitatively by studies on large numbers of patient samples, and panels need to be
developed that have a high degree of reliability. We are currently planning validation studies
of several biomarker protein panels that are designed to not only detect a particular kind of
cancer, but to also predict the most likely subtype. These panels seem to be very promising
for therapy guidance, but their predictive value needs to be determined rigorously.
From a bioanalytical science point of view, we have learned in our research that combining
nanostructured electrodes with magnetic particle-antibody-HRP multi-label particles
provides ultrahigh sensitivity, accuracy, flexibility, and low cost. The advantages of
combining multiplexed immunoassays and microfluidics are realized in semi-automation,
improved analysis speed, decrease of sample size into the low μL range, and higher signal/
noise ratios. Further automation of immunoassays in more advanced microfluidic systems
are underway as this article was being written.
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Finally, in keeping with the theme of this special issue, our studies are built upon the solid
foundation of early research discoveries in polarography, polarographic instrumentation and
electrochemical enzyme catalysis that was initiated and pursued in Heyrovsky’s
Polarographic Institute. Our sincere thanks are due to Professors Heyrovsky and Zuman and
their early research colleagues for the immense and valuable legacy they have left us.
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Fig. 1.
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Protocols for electrochemical immunosensors illustrated for a gold nanoparticle sensor using
a single enzyme label (path A) or a multi-labeled nanoparticle (path B). The sensor features
primary antibodies (Ab1) that capture the analyte protein from the sample. In the
conventional approach (path A), an enzyme-labeled secondary antibody (Ab2) is added that
binds to the analyte protein on the surface. In the high sensitivity approach (path B) a
nanoparticle with antibodies and thousands of enzyme labels is added to bind to the analyte
protein. Addition of an enzyme substrate and electrochemical detection provides signals
proportional to the amount of protein in the sample.

NIH-PA Author Manuscript
Chem Rec. Author manuscript; available in PMC 2012 August 01.

RUSLING

Page 13

NIH-PA Author Manuscript
Fig. 2.

Amplification strategies for electrochemical immunosensors using nanoparticles or other
moieties attached to secondary antibody (Ab2).

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Chem Rec. Author manuscript; available in PMC 2012 August 01.

RUSLING

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig. 3.

Atomic force microscope images of immunosensor platforms: (a) SWCNT forest on silicon;
(b) SWCNT forest coated with chemically attached antibodies; (c) a PDDA/gold
nanoparticle (AuNP) bilayer on smooth mica; (d) phase contrast image of the same PDDA/
AuNP bilayer on mica; (e) anti-PSA antibodies attached onto carboxylate groups of the
AuNP/PDDA bilayer. Images (a) and (b) reproduced with permission from reference [62].
Images (c), (d), and (e) reproduced with permission from reference [50].
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Fig. 4.

Measurement of PSA in prostate cancer cells using SWCNT forest immunosensors: (A)
Micrograph of representative prostate cancer biopsy stained to reveal areas of tumor cells
(scale bar 100 microns). Cells subsequently isolated by laser microdissection for PSA
detection. (B) Sensor response at −0.3 V and 3000 rpm for tissue lysates (~1000 cells) in 10
μL buffer followed by 10 μL anti-PSA-CNT-HRP bioconjugate (11 pmol mL−1 in HRP) in
0.05% Tween-20. Reproduced with permission from reference [62].
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Fig. 5.

Amperometric responses for AuNP immunosensors at −0.3 V and 3000 rpm in buffer
containing 1 mM hydroquinone after injecting 0.04 mM H2O2 to develop the signal (A)
using Ab2-magnetic bead-HRP with 7500 labels/bead at PSA concentrations shown.
Controls: (a) Immunosensors built on bare PG at 10 pg mL−1 PSA; (b) Immunosensors built
on PDDA coated PG surface at 10 pg mL−1 PSA. (B) Influence of PSA concentration on
steady state current for AuNP immunosensor using multi-label Ab2-magnetic bead-HRP.
Reproduced with permission from reference [50].
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Fig. 6.
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Validation of accuracy of nanostructured four-sensor immunoarray for human serum
samples showing correlation with results from ELISA for: (A) PSA, (B) prostate specific
membrane antigen (PSMA), (C) platelet factor-4 (PF-4), (D) interleukin-6 (IL-6). Samples
numbered 1-10 are from prostate cancer patients; samples 11–14 are controls from cancerfree individuals showing much lower protein levels.
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Fig. 7.
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Microfluidic protein array: (A) microfluidic array chip, pump (bottom left), and sample
injector. The eight-sensor microfluidic device is in the red box, expanded at top with
arrangement of eight nanostructured sensors (black dots), Pt counter and Ag/AgCl reference
electrodes shown above. (B) Illustration of use of the array for immunoassays showing one
sensing element and massively labeled (7,000–400,000 horseradish peroxidases) 1 mm
magnetic particle with multiple secondary antibodies (Ab2) attached. The magnetic particle
captures protein analytes from serum off-line, is washed and magnetically separated, then
injected into the microfluidic device, and captured by antibodies (Ab1) on the elements of
the sensor chip for amperometric measurement using H2O2 and hydroquinone mediator to
activate the HRP label. Reproduced with permission from reference [66].
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Fig. 8.
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Simultaneous calibration using eight-sensor microfluidic array with off-line analyte capture
by multi-label HRP-MP-Ab2 particles using 200,000 HRP labels per particle for PSA and
IL-6 in serum. Signals developed by injecting 1 mM hydroquinone mediator + 100 mM
hydrogen peroxide as enzyme activator. (C) Simultaneous determinations by the array
compared to individual ELISAs for PSA and IL-6 in patient serum: 1–4 are from prostate
cancer patients; 5 is a cancer-free control. Reproduced with permission from reference [66].
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Fig. 9.

NIH-PA Author Manuscript

Representation of ECL immunoarray showing wells on a 1 × 1 in. pyrolytic graphite chip.
SWCNT forests are surrounded by hydrophobic polymer (white) to make microwells on the
chip. with SWCNT forests decorated with primary antibodies in the bottom. RuBPY-silica
detection nanoparticles with cognate secondary antibodies are added and bind to the
captured protein analytes. The chip is placed in an open top electrochemical cell, 0.95 V vs.
SCE is applied, and ECL is detected by a CCD camera in a dark box. Reproduced with
permission from reference [74].
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Detection of PSA and IL-6 in calf serum using ECL microwell arrays at 0.95 V vs. Ag/AgCl
in the presence of 0.05% Tween 20 + 0.05% Triton-X 100 + 100 mM TPrA in 0.2 M
phosphate buffer (pH 7.5). CCD images of ECL immunoarrays for (A) PSA at (1) 10 ng
mL−1, (2) 0.4 ng mL−1, (3) 1 pg mL−1, (4) 0 pg mL−1 (control). (B) IL-6 at (1) 2 ng mL−1,
(2) 0.2 ng mL−1, (3) 0.1 pg mL−1, (4) 0 pg mL−1 (control). Reproduced with permission
from reference [74].
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Scheme 1.

Detection of proteins using HRP (PFeIII) labels.
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